Praxair Distribution v. Mallinckrodt Hospital — Federal Circuit Holds Nitric Oxide Dosing Method Patent Ineligible
The Federal Circuit held Mallinckrodt’s patents on methods of supplying inhaled nitric oxide therapy while monitoring patients for adverse effects were patent-ineligible under § 101 — finding the claims directed to the natural phenomenon that nitric oxide can worsen pulmonary edema in certain patients and the monitoring and adjusting steps conventional therapeutic practice.